HeartBeam shares surge 45.78% premarket after outlining regulatory strategy following FDA's Not Substantially Equivalent decision.

HeartBeam surged 45.78% in premarket trading following its announcement of a regulatory strategy in response to the FDA’s Not Substantially Equivalent determination. The company’s outline of its path forward after the regulatory hurdle likely spurred investor optimism, driving the sharp premarket increase.